EUVIMEDEUVIMED entdecken
Crossref

Is second 131I treatment necessary for differentiated thyroid cancer patients and who could not benefit from it? A real-world retrospective study in China

Canran Xiao, Ruoxin Xu, Yao Luo, Zeqing Xu, Caihua Tang

Annals of Nuclear Medicine · 2025

DOI: 10.1007/s12149-024-01984-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2025. Verfasst von Canran Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, China. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The efficacy of a second radioactive iodine-131 (131I) treatment in patients with differentiated thyroid cancer (DTC) who did not achieve an excellent response (ER) following initial 131I therapy remains controversy and the population that would derive limited benefit from it is currently unclear. OBJECTIVES: The aim of this retrospective study was to assess the efficacy of the second 131I treatment in DTC patients with non-ER after the initial 131I therapy, and to identify potential risk factors associated with non-benefit of the second 131I treatment. METHODS: 127 DTC patients who underwent two 131I treatments following thyroidectomy were included in this study, and the therapeutic response was evaluated after each 131I treatment. Beneficial treatment was defined as an improvement in therapy response grade (e.g. from indeterminate response to ER) after the second 131I treatment, while unbeneficial treatment was defined as no change or a downgrade in therapy response grade. The potential risk factors associated with the non-benefit of the second 131I treatment were identified using univariate and multivariate logistic regression models. RESULTS: Following the second 131I treatment, therapy responses of 55.12% (70/127) of patients were reclassified to a better grade indicating treatment benefit, while 44.88% (57/127) showed no change or were reclassified to a worse grade suggesting no benefit from treatment. The non-benefit of the second 131I treatment was significantly associated with potential risk factors including stimulated thyroglobulin (sTg) level ≥ 11.46 ng/mL before the second 131I treatment, primary tumor size > 2 cm, status T2 or higher, N1b status and ATA high risk. CONCLUSIONS: The study results demonstrated that more than half of DTC patients could potentially benefit from a second 131I therapy. However, over 40% of patients exhibited no benefit in response to the second 131I treatment, suggesting potential overtreatment for this subgroup. Therefore, clinicians should exercise meticulous and precise decision-making based on identified risk factors when considering the necessity of a second 131I treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsHumansRetrospective StudiesFemaleMaleMiddle AgedChinaAdultTreatment OutcomeAgedYoung AdultRisk Factors

Stichwörter der Autor:innen

Differentiated thyroid cancerExcellent responseIndeterminate responseRadiation exposureRadioactive iodine treatmentTherapy responseThyroglobulin

Substanzen

Iodine RadioisotopesIodine-131

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, China.
  • Department of Nuclear Medicine, Chongqing University Cancer Hospital, Chongqing, 400030, China.
  • Department of Nuclear Medicine, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, China. tangcaih@mail.sysu.edu.cn.

Zitieren

APA

Xiao, C., Xu, R., Luo, Y., Xu, Z., & Tang, C. (2025). Is second 131I treatment necessary for differentiated thyroid cancer patients and who could not benefit from it? A real-world retrospective study in China. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-024-01984-8

Vancouver

Xiao C, Xu R, Luo Y, Xu Z, Tang C. Is second 131I treatment necessary for differentiated thyroid cancer patients and who could not benefit from it? A real-world retrospective study in China. Annals of Nuclear Medicine. 2025. doi:10.1007/s12149-024-01984-8

BibTeX
@article{Xiao2025,
  author = {Xiao, Canran and Xu, Ruoxin and Luo, Yao and Xu, Zeqing and Tang, Caihua},
  title = {Is second 131I treatment necessary for differentiated thyroid cancer patients and who could not benefit from it? A real-world retrospective study in China},
  journal = {Annals of Nuclear Medicine},
  year = {2025},
  doi = {10.1007/s12149-024-01984-8}
}
Kostenlos starten →